Characterization and preclinical development of LCI-1, a selective and potent Chk1 inhibitor in phase 1 clinical trials

被引：4
|
作者：
Marshall, Mark
Barda, David
Barnard, Darlene
Cox, Karen
Diaz, H. Bruce
King, Constance
Nutter, Suzanne
Westin, Eric
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2009年 / 8卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-09-B248
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B248
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor
    Constance King
    Henry Diaz
    Darlene Barnard
    David Barda
    David Clawson
    Wayne Blosser
    Karen Cox
    Sherry Guo
    Mark Marshall
    Investigational New Drugs, 2014, 32 : 213 - 226
  • [2] Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor
    King, Constance
    Diaz, Henry
    Barnard, Darlene
    Barda, David
    Clawson, David
    Blosser, Wayne
    Cox, Karen
    Guo, Sherry
    Marshall, Mark
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (02) : 213 - 226
  • [3] Targeting the replication checkpoint with a potent and selective CHK1 inhibitor
    Parry, David
    Shanahan, Frances
    Davis, Nicole
    Wiswell, Derek
    Seghezzi, Wolfgang
    Pierce, Robert
    Hsieh, Yunsheng
    Paruch, Kamil
    Guzi, Timothy
    CANCER RESEARCH, 2009, 69
  • [4] Characterization and preclinical development of LY2606368, a second generation Chk1 inhibitor
    Marshall, M.
    King, C.
    Barnard, D.
    Diaz, H.
    Barda, D.
    Bence, A.
    Westin, E.
    EJC SUPPLEMENTS, 2010, 8 (07): : 65 - 65
  • [5] New chk1 inhibitor development & the feasibility of use of chk1 inhibitor with antimetabolite for NSCLC
    Chung, Injae
    CANCER RESEARCH, 2017, 77
  • [6] Preclinical characterization of ARRY-575: a potent, selective, and orally bio-available small molecule inhibitor of Chk1
    Humphries, M. J.
    von Carlowitz, I.
    Le Huerou, Y. L.
    Randolph, N.
    Gunawardana, I.
    Mohr, P. J.
    Wang, B.
    Lyon, M. A.
    Chicarelli, M.
    Sullivan, F.
    Blake, J. F.
    Winski, S. L.
    Wallace, E.
    ANNALS OF ONCOLOGY, 2011, 22 : 23 - 23
  • [7] Characterization of a novel, oral Chk1 inhibitor
    von Carlowitz, Ira
    Le Huerou, Yvan
    Humphries, Michael
    Ganster, Susan
    Raddatz, Nicholas
    Randolph, Nikole
    Sullivan, Francis
    Mohr, Peter
    Wang, Bin
    Gunawardana, Indrani
    Chicarelli, Mark
    Lyon, Michael
    Blake, James
    Schrag, Michael
    Winski, Shannon
    Wallace, Eli
    CANCER RESEARCH, 2009, 69
  • [8] Synthesis and development of potent Chk1 kinase inhibitors
    Huang, Shaei
    Garbaccio, Rob
    Tasber, Edward S.
    Fraley, Mark E.
    Steen, Justin T.
    Yan, Youwei
    Munshi, Sanjieev
    Ikuta, Mari
    Kuo, Lawrence
    Kreatsoulas, Constantine
    Reilly, Michael
    Mahan, Elizabeth
    Stirdivant, Steve
    Drakas, Bob
    Rickert, Keith
    Walsh, Eileen
    Hamilton, Kelly
    Buser, Carolyn A.
    Hardwick, James
    Mao, Xianzhi
    Beck, Steve
    Abrams, Marc
    Tao, Weikang
    Lobell, Rob
    Sepp-Lorenzino, Laura
    Hartman, George D.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 238
  • [9] Characterization of the CHK1 Allosteric Inhibitor Binding Site
    Vanderpool, Darin
    Johnson, Ted O.
    Ping, Chen
    Bergqvist, Simon
    Alton, Gordon
    Phonephaly, Soneprasith
    Rui, Eugene
    Luo, Chun
    Deng, Ya-Li
    Grant, Stephan
    Quenzer, Terri
    Margosiak, Steve
    Register, James
    Brown, Ed
    Ermolieff, Jacques
    BIOCHEMISTRY, 2009, 48 (41) : 9823 - 9830
  • [10] Investigational CHK1 inhibitors in early phase clinical trials for the treatment of cancer
    Dent, Paul
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (12) : 1095 - 1100
12345